Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Twist Bioscience Corp — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.36 (market cap $77.43B), while Twist Bioscience Corp trades at $160.14 (market cap $10.08B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 7.7× Twist Bioscience Corp's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Twist Bioscience Corp for 27 Days on average.
| MDLZ | TWST | |
|---|---|---|
Market Cap | $77.43B | $10.08B |
Volume | 7,695,104 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $205.00 |
52-Week Low | $51.51 | $25.45 |
Typical Hold Time | 107 Days | 27 Days |
Enterprise Value | $97.78B | $10.01B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.39, up 1.7% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations, supported by $38.54B revenue in 2025. Recent dividend increase to $0.52 per share and positive media coverage highlight management's confidence in cash flow stability. Valuation metrics include P/E of 22.22 and P/S of 1.97, trading below the consensus price target of $70.29.
MDLZ presents a compelling investment case with 76% analyst buy ratings and 16% upside to target, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 pose near-term risks. The company's global brand portfolio and emerging market growth provide long-term stability, but investors should monitor commodity inflation's impact on profitability amid current neutral oscillator signals.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
